Regeneron drug for disease that causes dangerous bone growth earns FDA approval

FDA approves Regeneron’s drug for ultra-rare disease that turns tissue to bone

FDA approved Regeneron's Pasatru (garetosmab) for FOP, a rare disease affecting ~900 patients. Annual list price ranges $693K–$2.1M based on weight.